3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rosmarinic acid-induced apoptosis and cell cycle arrest in triple-negative breast cancer cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rosmarinic acid (RA) is a polyphenolic compound with various pharmacological properties, including, anti-inflammatory, immunomodulatory, and neuroprotective, as well as having antioxidant and anticancer activities. This study evaluated the effects and mechanisms of RA in two racially different triple-negative breast cancer (TNBC) cell lines. Results obtained show that RA significantly caused cytotoxic and antiproliferative effects in both cell lines in a dose- and time-dependent manner. Remarkably, RA induced cell cycle arrest-related apoptosis and altered the expression of many apoptosis-involved genes differently. In MDA-MB-231 cells, RA arrested the cells in the G 0/G 1 phase. In contrast, the data suggest that RA causes S-phase arrest in MDA-MB-468 cells, leading to a 2-fold increase in the apoptotic effect compared to MDA-MB-231 cells. Further, in MDA-MB-231 cells, RA significantly upregulated the mRNA expression of three genes: harakiri ( HRK), tumor necrosis factor receptor superfamily 25 ( TNFRSF25), and BCL-2 interacting protein 3 ( BNIP3). In contrast, in the MDA-MB-468 cell line, the compound induced a significant transcription activation in three genes, including TNF, growth arrest and DNA damage-inducible 45 alpha ( GADD45A), and BNIP3. Furthermore, RA repressed the expression of TNF receptor superfamily 11B ( TNFRSF11B) in MDA-MB-231 cells in comparison to the ligand TNF superfamily member 10 ( TNFSF10) and baculoviral IAP repeat-containing 5 (BIRC5) in MDA-MB-468 cells. In conclusion, the data suggest that the polyphenol RA may have a potential role in TNBC therapies, particularly in MDA-MB-468 cells.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains.

          While hypoxia-inducible factor (HIF) is a major actor in the cell survival response to hypoxia, HIF also is associated with cell death. Several studies implicate the HIF-induced putative BH3-only proapoptotic genes bnip3 and bnip3l in hypoxia-mediated cell death. We, like others, do not support this assertion. Here, we clearly demonstrate that the hypoxic microenvironment contributes to survival rather than cell death by inducing autophagy. The ablation of Beclin1, a major actor of autophagy, enhances cell death under hypoxic conditions. In addition, the ablation of BNIP3 and/or BNIP3L triggers cell death, and BNIP3 and BNIP3L are crucial for hypoxia-induced autophagy. First, while the small interfering RNA-mediated ablation of either BNIP3 or BNIP3L has little effect on autophagy, the combined silencing of these two HIF targets suppresses hypoxia-mediated autophagy. Second, the ectopic expression of both BNIP3 and BNIP3L in normoxia activates autophagy. Third, 20-mer BH3 peptides of BNIP3 or BNIP3L are sufficient in initiating autophagy in normoxia. Herein, we propose a model in which the atypical BH3 domains of hypoxia-induced BNIP3/BNIP3L have been designed to induce autophagy by disrupting the Bcl-2-Beclin1 complex without inducing cell death. Hypoxia-induced autophagy via BNIP3 and BNIP3L is clearly a survival mechanism that promotes tumor progression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics

            Various physiological processes involve appropriate tissue developmental process and homeostasis - the pathogenesis of several diseases connected with deregulatory apoptosis process. Apoptosis plays a crucial role in maintaining a balance between cell death and division, evasion of apoptosis results in the uncontrolled multiplication of cells leading to different diseases such as cancer. Currently, the development of apoptosis targeting anticancer drugs has gained much interest since cell death induced by apoptosis causes minimal inflammation. The understanding of complexities of apoptosis mechanism and how apoptosis is evolved by tumor cells to oppose cell death has focused research into the new strategies designed to induce apoptosis in cancer cells. This review focused on the underlying mechanism of apoptosis and the dysregulation of apoptosis modulators involved in the extrinsic and intrinsic apoptotic pathway, which include death receptors (DRs) proteins, cellular FLICE inhibitory proteins (c-FLIP), anti-apoptotic Bcl-2 proteins, inhibitors of apoptosis proteins (IAPs), tumor suppressor (p53) in cancer cells along with various current clinical approaches aimed to selectively induce apoptosis in cancer cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Apoptosis: a link between cancer genetics and chemotherapy.

              Defects in apoptosis underpin both tumorigenesis and drug resistance, and because of these defects chemotherapy often fails. Understanding the molecular events that contribute to drug-induced apoptosis, and how tumors evade apoptotic death, provides a paradigm to explain the relationship between cancer genetics and treatment sensitivity and should enable a more rational approach to anticancer drug design and therapy.
                Bookmark

                Author and article information

                Journal
                1254354
                3614
                Eur J Pharmacol
                Eur J Pharmacol
                European journal of pharmacology
                0014-2999
                1879-0712
                24 September 2020
                01 August 2020
                15 October 2020
                15 October 2020
                : 885
                : 173419
                Affiliations
                Division of Pharmaceutical Sciences, College of Pharmacy & Pharmaceutical Sciences, Florida A&M University, 1415 ML King Blvd, Room G 134 H New Pharmacy Building, Tallahassee, FL, 32307, United States
                Author notes

                Authors’ contributions

                Conceptualization, SSM and KFAS; methodology, SSM and AA; software, SSM; validation, SSM, KFAS, and AA; formal analysis, SSM and AA; investigation, SSM, KFAS, and AA; resources, KFAS; data curation, SSM and KFAS; writing original draft, SSM; writing – review & editing: SSM, NZ, AA, and KFAS; visualization, SSM; supervision, SSM and KFAS; project administration, SSM and KFAS; funding acquisition, KFAS. All authors read and approved the manuscript and accept to be responsible for all aspects of the research in ensuring that the accuracy or integrity of any part of the work is properly considered.

                [* ]Corresponding author. karam.soliman@ 123456famu.edu (K.F.A. Soliman).
                Article
                NIHMS1622763
                10.1016/j.ejphar.2020.173419
                7541730
                32750370
                ac1dad23-7b19-411e-9aac-e50ea88feb4b

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                Pharmacology & Pharmaceutical medicine
                rosmarinic,triple-negative breast cancer,apoptosis,cell cycle,gene expression

                Comments

                Comment on this article